Nucleoside News and Research

RSS

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022

WHO lists the Comirnaty COVID-19 mRNA vaccine for emergency use

The World Health Organization today listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO since the outbreak began a year ago.

2 Jan 2022

New oral pill for COVID-19 home treatment

As cases and hospitalizations continue to rise in many countries, new treatments are being sought to arrest the progression of the disease, preventing severe illness and death or disability. One such is the small molecule molnupiravir, the focus of a new research paper.

20 Dec 2021

New mRNA vaccine platform provides stronger protection against SARS-CoV-2 delta variant

A group of researchers from various institutions developed a nucleoside-modified mRNA vaccine that encodes the SARS-CoV-2 N protein (mRNA-N) and is formulated in lipid nanoparticles for this investigation (LNP).

14 Dec 2021

Newly discovered hormone may play a key role in the development of type 1 and type 2 diabetes

A newly discovered hormone named fabkin helps regulate metabolism and may play an important role in the development of both type 1 and type 2 diabetes, according to research led by the Sabri Ülker Center for Metabolic Research at Harvard T.H. Chan School of Public Health.

12 Dec 2021

New hormone may play a key role in the development of type 1 and type 2 diabetes

8 Dec 2021

Study suggests efficacy of SARS-CoV-2 main protease inhibitors is not compromised in current COVID-19 variants

A new study has focussed on assessing the Mpro mutants of newly emerged SARS-CoV-2 variants.

2 Dec 2021

First long-acting injectable HIV treatment appraised and approved by NICE

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

19 Nov 2021

Study shows 90.7% efficacy for the BNT162b2 COVID vaccine in 5-11 year-olds

A new study evaluates the safety, immunogenicity, and efficacy of the BNT162b2 in children who were 5 to 11 years of age.

11 Nov 2021

Antidepressant Prozac could offer the first treatment for atrophic macular degeneration

An antidepressant best known as Prozac could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.

21 Oct 2021

Research may lead to breakthroughs in combating cancer drug resistances

New research has revealed the differences in mechanism behind cancer’s resistance to the major class of anti-cancer drugs known as nucleoside analogues.

20 Oct 2021

The biochemical mechanisms of remdesivir-mediated RNA synthesis inhibition

A new preprint suggests a fruitful approach to develop such drugs based on biochemical and molecular modeling studies of the drug remdesivir.

19 Oct 2021

Nucleoside modifications suppress the potential of RNA to activate dendritic cells

A new paper shows that human TLR3, TLR7, and TLR8 receptors are activated with naturally occurring RNA, but this is eliminated once modified nucleosides such as m5C, m6A, m5U s2U, or pseudouridine are incorporated.

12 Oct 2021

Lipids, COVID-19, and host immunity

A new study from a team of researchers at the University of Pennsylvania examines the role played by lipids in this disease.

10 Oct 2021

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

A recent study assesses the serological and cellular responses to Pfizer’s BNT162b2 mRNA vaccine in people aged 80-96 years.

4 Oct 2021

Difficulties of stability and storage of mRNA COVID-19 vaccines

Two researchers have collaborated to review the difficulties faced in storing and transporting these vaccines in a manner that will keep them stable.

4 Oct 2021

Damaging DNA builds up in the eyes to drive blinding age-related macular degeneration

Damaging DNA builds up in the eyes of patients with geographic atrophy, an untreatable, poorly understood form of age-related macular degeneration that causes blindness, new research from the University of Virginia School of Medicine reveals.

1 Oct 2021

Design of mRNA vaccines to combat COVID-19

A recent review study discusses fundamental concepts in the successful delivery of nucleic acids in therapeutics.

23 Sep 2021

SARS-CoV-2 genome signature leads to replicative advantage in presence of Remdesivir

A new study indicates that low-level resistance of SARS-CoV-2 to remdesivir is not widespread and dissimilar to other RNA viruses revealing evolutionary predictability of this pandemic virus.

22 Sep 2021

Is the Pfizer-BioNTech COVID vaccine still effective after 6 months?

A team of researchers assessed the effectiveness of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine.

21 Sep 2021